As Union Therapeutics gets ready for its next clinical studies for Covid-19 with its variant of the anti-inflammatory drug Niclosamide, the company announces it is testing two different approaches to the illness.
So far, the company has only gone on the record about the nebulized variant of the drug, that is, when it is atomized and inhaled, but the firm is also working on a variant of the drug in the form of a nasal spray, and according to Union Therapeutics Chief Financial Officer Morten Boesen, there is a good reason for it.
Get full access for you and your coworkers.Start a free company trial today
Already a member? Log in.